Article
[Pharmacogenomic control of angiotensin converting enzyme gene I/D polymorphism predominant risk factor of development of chronic heart failure and target of enalapril treatment].
Kardiologiia - 1 Jan 2013
Tepliakov A T, Shilov S N, Berezikova E N, Efremov A V, Safronov I D, Pustovetova M G, Maianskaia S D, Torim Iu Iu, Karpov R S
Abstract excerpt
Aim of investigation - to study effect of angiotensin-converting enzyme (ACE) gene polymorphism as a dominant risk factor of development of chronic heart failure (CHF) and target for effective therapy with ACE inhibitor enalapril in patients with ischemic heart disease. We followed 226 patients with CHF on stable permanent basic therapy comprising -adrenoblocker, diuretic, aldosterone antagonist, digoxin, and ACE...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.